|
1
|
Mukherjee TK, Malik P and Hoidal JR: The
emerging role of estrogen related receptorα in complications of
non-small cell lung cancers. Oncol Lett. 21(258)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Min HY and Lee HY: Mechanisms of
resistance to chemotherapy in non-small cell lung cancer. Arch
Pharm Res. 44:146–164. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Postmus PE, Kerr KM, Oudkerk M, Senan S,
Waller DA, Vansteenkiste J, Escriu C and Peters S: ESMO Guidelines
Committee. Early and locally advanced non-small-cell lung cancer
(NSCLC): ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 28 (Suppl 4):iv1–iv21. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Alcibar OL, Nadal E, Romero Palomar I and
Navarro-Martin A: Systematic review of stereotactic body
radiotherapy in stage III non-small cell lung cancer. Transl Lung
Cancer Res. 10:529–538. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
D'Aniello C, Berretta M, Cavaliere C,
Rossetti S, Facchini BA, Iovane G, Mollo G, Capasso M, Pepa CD,
Pesce L, et al: Biomarkers of prognosis and efficacy of
anti-angiogenic therapy in metastatic clear cell renal cancer.
Front Oncol. 9(1400)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dall'Olio FG, Abbati F, Facchinetti F,
Massucci M, Melotti B, Squadrilli A, Buti S, Formica F, Tiseo M and
Ardizzoni A: CEA and CYFRA 21-1 as prognostic biomarker and as a
tool for treatment monitoring in advanced NSCLC treated with immune
checkpoint inhibitors. Ther Adv Med Oncol.
12(1758835920952994)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hatzakis KD, Froudarakis ME, Bouros D,
Tzanakis N, Karkavitsas N and Siafakas NM: Prognostic value of
serum tumor markers in patients with lung cancer. Respiration.
69:25–29. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wu H, Wang Q, Liu Q, Zhang Q, Huang Q and
Yu Z: The serum tumor markers in combination for clinical diagnosis
of lung cancer. Clin Lab. 66:2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Popper HH, Ryska A, Tímár J and Olszewski
W: Molecular testing in lung cancer in the era of precision
medicine. Transl Lung Cancer Res. 3:291–300. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Guo Y, Cao R, Zhang X, Huang L, Sun L,
Zhao J, Ma J and Han C: Recent progress in rare oncogenic drivers
and targeted therapy for non-small cell lung cancer. Onco Targets
Ther. 12:10343–10360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Alzofon N and Jimeno A: Capmatinib for
non-small cell lung cancer. Drugs Today (Barc). 57:17–25.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li LJ, Chang WM and Hsiao M: Aberrant
expression of microrna clusters in head and neck cancer development
and progression: Current and future translational impacts.
Pharmaceuticals (Basel). 14(194)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Papanota AM, Karousi P, Kontos CK,
Ntanasis-Stathopoulos I, Scorilas A and Terpos E: Multiple myeloma
bone disease: Implication of MicroRNAs in its molecular background.
Int J Mol Sci. 22(2375)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hammouz RY, Kołat D, Kałuzińska Ż,
Płuciennik E and Bednarek AK: MicroRNAs: Their role in metastasis,
angiogenesis, and the potential for biomarker utility in bladder
carcinomas. Cancers (Basel). 13(891)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Raue R, Frank AC, Syed SN and Brüne B:
Therapeutic targeting of MicroRNAs in the tumor microenvironment.
Int J Mol Sci. 22(2210)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu C, Hu W, Li LL, Wang YX, Zhou Q, Zhang
F, Song-Yang YY, Zhu W, Sun CC and Li DJ: Roles of miR-200 family
members in lung cancer: More than tumor suppressors. Future Oncol.
14:2875–2886. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xie K, Wang C, Qin N, Yang J, Zhu M, Dai
J, Jin G, Shen H, Ma H and Hu Z: Genetic variants in regulatory
regions of microRNAs are associated with lung cancer risk.
Oncotarget. 7:47966–47974. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wei S, Wang K, Huang X and Zhao Z and Zhao
Z: LncRNA MALAT1 contributes to non-small cell lung cancer
progression via modulating miR-200a-3p/programmed death-ligand 1
axis. Int J Immunopathol Pharmacol.
33(2058738419859699)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li H, Feng C and Shi S: miR-196b promotes
lung cancer cell migration and invasion through the targeting of
GATA6. Oncol Lett. 16:247–252. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cheung WK, Zhao M, Liu Z, Stevens LE, Cao
PD, Fang JE, Westbrook TF and Nguyen DX: Control of alveolar
differentiation by the lineage transcription factors GATA6 and HOPX
inhibits lung adenocarcinoma metastasis. Cancer Cell. 23:725–738.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zang Q, Xu L, Li J and Jia H: GATA6
activated long non-coding RNA PCAT1 maintains stemness of non-small
cell lung cancer by mediating FRK. J BUON. 25:2371–2381.
2020.PubMed/NCBI
|
|
22
|
Dong H, Weng C, Bai R, Sheng J, Gao X, Li
L and Xu Z: The regulatory network of miR-141 in the inhibition of
angiogenesis. Angiogenesis. 22:251–262. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ren Y, Qiu H, Yuan Y, Ye J, Tian Y, Wen B,
Zhang W and Li Q: Evaluation of 7th edition of AJCC staging system
for nasopharyngeal carcinoma. J Cancer. 8:1665–1672.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cheng Y, Qu X, Dong Z, Zeng Q, Ma X, Jia
Y, Li R, Jiang X, Williams C, Wang T and Xia W: Comparison of serum
exosome isolation methods on co-precipitated free microRNAs. PeerJ.
8(e9434)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Madadi S and Soleimani M: Comparison of
miR-16 and cel-miR-39 as reference controls for serum miRNA
normalization in colorectal cancer. J Cell Biochem. 120:4802–4803.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lee H, Kim C, Kang H, Tak H, Ahn S, Yoon
SK, Kuh HJ, Kim W and Lee EK: microRNA-200a-3p increases
5-fluorouracil resistance by regulating dual specificity
phosphatase 6 expression. Exp Mol Med. 49(e327)2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet.
48:607–616. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cancer Genome Atlas Research Network.
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhang J, Zhu N and Chen X: A novel long
noncoding RNA LINC01133 is upregulated in lung squamous cell cancer
and predicts survival. Tumour Biol. 36:7465–7471. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhong S, Golpon H, Zardo P and Borlak J:
miRNAs in lung cancer. A systematic review identifies predictive
and prognostic miRNA candidates for precision medicine in lung
cancer. Transl Res. 230:164–196. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Peng L, Wang Y, Liu F, Qiu X, Zhang X,
Fang C, Qian X and Li Y: Peripheral blood markers predictive of
outcome and immune-related adverse events in advanced non-small
cell lung cancer treated with PD-1 inhibitors. Cancer Immunol
Immunother. 69:1813–1822. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tanizaki J, Haratani K, Hayashi H, Chiba
Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K,
et al: Peripheral blood biomarkers associated with clinical outcome
in non-small cell lung cancer patients treated with nivolumab. J
Thorac Oncol. 13:97–105. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Weidle UH, Birzele F and Nopora A:
MicroRNAs as potential targets for therapeutic intervention with
metastasis of non-small cell lung cancer. Cancer Genomics
Proteomics. 16:99–119. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen Y, Peng W, Lu Y, Chen J, Zhu YY and
Xi T: MiR-200a enhances the migrations of A549 and SK-MES-1 cells
by regulating the expression of TSPAN1. J Biosci. 38:523–532.
2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
He Q, Fang Y, Lu F, Pan J, Wang L, Gong W,
Fei F, Cui J, Zhong J, Hu R, et al: Analysis of differential
expression profile of miRNA in peripheral blood of patients with
lung cancer. J Clin Lab Anal. 33(e23003)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shen Y, Pan X and Yang J: Gene regulation
and prognostic indicators of lung squamous cell carcinoma:
TCGA-derived miRNA/mRNA sequencing and DNA methylation data. J Cell
Physiol. 234:22896–22910. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chen W, Chen Z, Zhang M, Tian Y, Liu L,
Lan R, Zeng G, Fu X, Ru G, Liu W, et al: GATA6 exerts potent lung
cancer suppressive function by inducing cell senescence. Front
Oncol. 10(824)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fumagalli C, Bianchi F, Raviele PR,
Vacirca D, Bertalot G, Rampinelli C, Lazzeroni M, Bonanni B,
Veronesi G, Fusco N, et al: Circulating and tissue biomarkers in
early-stage non-small cell lung cancer. Ecancermedicalscience.
11(717)2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Halvorsen AR, Bjaanæs M, LeBlanc M, Holm
AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC,
López-Guerrero JA, et al: A unique set of 6 circulating microRNAs
for early detection of non-small cell lung cancer. Oncotarget.
7:37250–37259. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang C, Ding M, Xia M, Chen S, Van Le A,
Soto-Gil R, Shen Y, Wang N, Wang J, Gu W, et al: A Five-miRNA panel
identified from a multicentric case-control study serves as a novel
diagnostic tool for ethnically diverse non-small-cell lung cancer
patients. EBioMedicine. 2:1377–1385. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Fan X, Chen X, Feng Q, Peng K, Wu Q,
Passerini AG, Simon SI and Sun C: Downregulation of GATA6 in
mTOR-inhibited human aortic endothelial cells: Effects on
TNF-α-induced VCAM-1 expression and monocytic cell adhesion. Am J
Physiol Heart Circ Physiol. 316:H408–H420. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Si L, Tian H, Yue W, Li L, Li S, Gao C and
Qi L: Potential use of microRNA-200c as a prognostic marker in
non-small cell lung cancer. Oncol Lett. 14:4325–4330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mongroo PS and Rustgi AK: The role of the
miR-200 family in epithelial-mesenchymal transition. Cancer Biol
Ther. 10:219–222. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Xu-Welliver M and Carbone DP: Blood-based
biomarkers in lung cancer: Prognosis and treatment decisions.
Transl Lung Cancer Res. 6:708–712. 2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sun X, Wang M, Xu R, Zhang D, Liu A, Wang
Y, Lu T, Xin Y, Zhao Y, Xuan Y, et al: Prognostic model based on
circular RNA circPDK1 for resected lung squamous cell carcinoma.
Transl Lung Cancer Res. 8:907–919. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hu H, Sun Z, Li Y, Zhang Y, Li H, Zhang Y,
Pan Y, Shen L, Wang R, Sun Y and Chen H: The histologic
classifications of lung adenocarcinomas are discriminable by unique
lineage backgrounds. J Thorac Oncol. 11:2161–2172. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Nakajima N, Yoshizawa A, Nakajima T,
Hirata M, Furuhata A, Sumiyoshi S, Rokutan-Kurata M, Sonobe M,
Menju T, Miyamoto E, et al: GATA6-positive lung adenocarcinomas are
associated with invasive mucinous adenocarcinoma morphology,
hepatocyte nuclear factor 4α expression, and KRAS mutations.
Histopathology. 73:38–48. 2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Masaoutis C, Mihailidou C, Tsourouflis G
and Theocharis S: Exosomes in lung cancer diagnosis and treatment.
From the translating research into future clinical practice.
Biochimie. 151:27–36. 2018.PubMed/NCBI View Article : Google Scholar
|
